Mineralys Therapeutics, INC

Mineralys Therapeutics announced the pricing of a $150 million underwritten offering of its common stock at $26.50 per share.

Mineralys Therapeutics has amended its license agreement for lorundrostat, eliminating future royalty payments and securing a $500 million senior secured term loan facility.

Mineralys Therapeutics stockholders re-elected three Class III directors and ratified the appointment of Ernst & Young LLP as the company's independent auditor.

Mineralys Therapeutics announced first quarter 2026 financial results, highlighting the FDA's acceptance of its New Drug Application for lorundrostat with a PDUFA target date of December 22, 2026.

Mineralys Therapeutics announced FDA acceptance of its New Drug Application for lorundrostat for hypertension, setting a PDUFA target date of December 22, 2026, alongside its Q4 and full-year 2025 financial results.

Mineralys Therapeutics announced the submission of a New Drug Application for lorundrostat to the FDA and confirmed it is on track to report Phase 2 Explore-OSA trial results in Q1 2026.

Mineralys Therapeutics reports Q1 2026 financial results, highlighting progress on its NDA for lorundrostat and a cash position of $646.1 million.

Mineralys Therapeutics reports strong clinical trial results for lorundrostat in hypertension and chronic kidney disease, bolstering its path to an NDA submission in late 2025 or early 2026.

Mineralys Therapeutics announced positive pivotal and Phase 2 clinical trial results for lorundrostat in hypertension and chronic kidney disease, while securing significant capital.

Mineralys Therapeutics announces positive results from pivotal trials for lorundrostat and reports its financial results for the first quarter of 2025, highlighting progress in clinical development and financial activities.

Mineralys Therapeutics reported a net loss of $56.3 million for the third quarter of 2024, while also providing updates on its ongoing clinical trials for lorundrostat.

Mineralys Therapeutics reported a net loss of $72.5 million for the first six months of 2024, while advancing its clinical trials for lorundrostat.

Mineralys Therapeutics submitted its lead hypertension drug, lorundrostat, for FDA approval and bolstered its financial position with significant capital raises, despite continued net losses.

Mineralys Therapeutics faces substantial net losses in 2024 while advancing its lead drug candidate, lorundrostat, through clinical trials targeting hypertension and related cardiorenal conditions.

Mineralys Therapeutics' 10-K filing details its common stock structure, anti-takeover provisions, and ongoing clinical trials for lorundrostat.

Eric Warren, Chief Commercial Officer of Mineralys Therapeutics, Inc., sold 7,438 shares of common stock on July 21, 2026 for $26.87 per share.

David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, Inc., sold 416 shares of common stock on July 17, 2026 for $26.53 per share.

Jon Congleton, Chief Executive Officer and a Director of Mineralys Therapeutics, Inc., sold 10,700 shares of common stock on July 13, 2026 for $27.24 per share.

David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, Inc., sold 20,407 shares of common stock on July 13, 2026.

David Rodman, Chief Medical Officer of Mineralys Therapeutics, Inc., reported transactions involving the acquisition and disposition of common stock, executed under a Rule 10b5-1 trading plan.

Jon Congleton, CEO of Mineralys Therapeutics, Inc., reported the sale of company stock totaling 75,000 shares under a pre-arranged 10b5-1 trading plan.

Mineralys Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, detailing proposals for director elections and auditor ratification, and providing information on executive compensation and corporate governance.

Mineralys Therapeutics has filed definitive additional proxy materials with the SEC.

Mineralys Therapeutics will hold its annual stockholder meeting virtually on May 22, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Mineralys Therapeutics has filed definitive additional proxy materials with the SEC.

Mineralys Therapeutics will hold its annual stockholder meeting virtually on May 22, 2024, to elect a director and ratify the appointment of its independent accounting firm.

Samsara BioCapital and affiliated entities increased their beneficial ownership in Mineralys Therapeutics, Inc. to 8.2% following a recent public offering.

RA Capital Management, L.P. and its affiliates increased their beneficial ownership in Mineralys Therapeutics, Inc. to 9.9% following a $30 million purchase in a September 2025 public offering.

Samsara BioCapital, L.P. and its affiliates have significantly increased their beneficial ownership in Mineralys Therapeutics, Inc. to 9.1% by acquiring 600,000 shares in a recent public offering.

RA Capital Management and its affiliates have significantly increased their beneficial ownership in Mineralys Therapeutics, Inc. to 9.9% of outstanding common stock through a recent $17.5 million investment in a public offering.

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have disclosed a 6.3% beneficial ownership stake in Mineralys Therapeutics Inc. as of December 31, 2025.

BlackRock, Inc. has reported a significant passive ownership stake of 5.2% in Mineralys Therapeutics Inc., holding over 4.1 million shares of common stock.

Catalys Pacific and its affiliates reported continued beneficial ownership of 13.5% of Mineralys Therapeutics, Inc.'s common stock as of June 30, 2025.

Andera Partners and affiliates report a reduced beneficial ownership of Mineralys Therapeutics, Inc. common stock to 4.2%.

Adams Street Partners, LLC and its affiliated funds have filed an amended Schedule 13G, reporting a collective passive beneficial ownership of 2.3% in Mineralys Therapeutics, Inc.'s common stock as of December 31, 2024.